| Source: HalifaxProj(inhibit) |
| Type: |
| Akt1 is involved in cellular survival pathways, by inhibiting apoptotic processes; Akt2 is an important signaling molecule in the insulin signaling pathway. It is required to induce glucose transport. Inhibitors: -Curcumin: downregulate AKT phosphorylation and signaling. -Resveratrol -Quercetin: inhibit the PI3K/AKT pathway. -Epigallocatechin Gallate (EGCG) -Luteolin and Apigenin: inhibit AKT phosphorylation |
| Myeloma - Plasma Cell Malignancy Alternative Names: Multiple myeloma, plasma cell myeloma Type: Hematologic malignancy / plasma cell cancer Origin: Malignant transformation and clonal expansion of antibody-producing plasma cells, usually within the bone marrow. Function/Characteristics: Myeloma cells produce monoclonal immunoglobulins or light chains and can disrupt normal bone marrow function, bone remodeling, renal function, and immune regulation. Common Features: Bone marrow infiltration, osteolytic bone lesions, anemia, elevated monoclonal protein, renal dysfunction, hypercalcemia, and impaired normal antibody production. Common Markers: CD38, CD138, BCMA (TNFRSF17), SLAMF7, and monoclonal immunoglobulin/light-chain expression. |
| 7437- | CYN, | Cynaropicrin disrupts tubulin and c-Myc-related signaling and induces parthanatos-type cell death in multiple myeloma |
| - | in-vitro, | Mye, | AMO1 | - | in-vivo, | Mye, | NA | - | in-vitro, | Mye, | KMS11 | - | in-vitro, | Mye, | JJN3 | - | in-vitro, | Mye, | MolP8 | - | in-vitro, | Mye, | L363 | - | in-vitro, | Mye, | H929 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:92 Cells:% prod#:% Target#:4 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid